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Abstract 
Background: Reduced noradrenaline levels have been reported to occur in the motor cortex of PD patients 
at post-mortem. Imaging techniques have recently become available to specifically study noradrenergic 
terminal function in vivo using PET. 
Methods: 30 PD patients and 12 healthy control subjects, comparable across age, sex, and cognitive 
performance underwent PET imaging with 11C-MeNER, a specific ligand of the noradrenaline transporter 
(NAT). Cortical NAT binding was compared at a voxel level using Statistical Parametric Mapping while 
cortical thickness was assessed using FreeSurfer software with MRI. 
Results: PD patients showed reduced 11C-MeNER binding in the primary motor cortex unrelated to cortical 
thickness; other cortical regions did not differ between groups. In a subgroup analysis, patients with higher 
Hoehn & Yahr stage exhibited more pronounced 11C-MeNER binding reductions. 
Conclusion: Loss of cortical noradrenergic projections to the primary motor cortex occurs in PD associated 
with disease stage. 
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Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder affecting several major neurotransmitter systems. 
In particular, post-mortem studies have reported considerable degeneration of the locus coeruleus (LC), 
which supplies the cortex with noradrenaline.1 At post-mortem, multiple brain regions were reported to 
exhibit reduced levels of noradrenaline, including cerebellar cortex, thalamus, and cerebral cortex including 
primary motor cortex.2-5 In vivo imaging using positron emission tomography (PET) with 18F-DOPA is a 
marker of aromatic aminoacid decarboxylase activity in monoaminergic terminals, including those of 
dopaminergic, serotonergic and noradrenergic neurons. Moore and colleagues reported a decreased signal 
specifically in PD motor cortex.6 Newer PET ligands based on a reboxetine structure, such as 11C-MeNER, 
provide a specific marker of noradrenaline transporter function,7,8 and a recently proposed MeNER PET 
analytical approach allowed in vivo estimation of cortical noradrenaline transporter availability in healthy 
subjects.9 
The objective of this 11C-MeNER PET study was to examine the hypothesis that noradrenaline transporter 
function is decreased in cortical regions of PD patients compared to matched healthy control (HC) subjects.  
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Methods 
Study design and participants 
We recruited 30 PD patients for imaging with 11C-MeNER PET. Inclusion criteria were: diagnosis of PD 
according to the Movement Disorder Society (MDS) consensus criteria,10 age 50 - 85 years, a geriatric 
depression scale (GDS-15) score <6, and Montreal cognitive assessment (MoCA) score >22. Exclusion 
criteria were: a diagnosis of dementia, receiving medication acting on the noradrenergic transporter, and 
significant white matter lesions. Total levodopa-equivalent daily doses (LEDD) were calculated as 
previously recommended.11 Olfaction was tested with the 16-item Sniffin’ Sticks battery. Motor symptoms 
were scored using the MDS Unified PD Rating Scale part III (MDS-UPDRS III) after 12 hours of medication 
abstinence. Clinical disease duration and modified Hoehn & Yahr stage were recorded. Presence of REM 
sleep behavior disorder (RBD) was assessed with overnight polysomnography and a clinical interview for 
features of dream enactment.12 Demography of PD patients was compared to 12 age and sex matched, 
cognitively normal (MoCA >26) and non-depressed (GDS-15 <6) HC subjects without a history of 
neurological disorders and with a normal brain MRI (Table 1). A volume of interest analysis of NAT density 
in subcortical structures of the 42 subjects was previously reported.12  
The study was approved by the local ethical committee. All subjects gave informed written consent 
according to the Declaration of Helsinki. 
 
11C-MeNER PET 
Details of 11C-MeNER radiosynthesis and image reconstruction and normalization are provided as 
supplementary material. A 4 mm Gaussian filter was applied to the normalized images before calculation 
of parametric maps of binding potentials non displaceable (BPND) using the simplified reference tissue 
model 2 (SRTM2). Voxel-wise calculations in PXMOD were initiated with time activity curves of the 
thalamus as a high binding region and the caudate as a low binding region; the efflux constant of the 
reference region was fixed at k2’ = 0.021 min-1 as previously published.7,9 BPND values of the left + right 
precentral and postcentral gyrus were extracted for group comparisons. 
 
MRI 
An MPRAGE sequence was acquired on a Siemens Magnetom Tim Trio scanner using a 32 channel 
headcoil and the following parameters: TR/TI/TE, 960/2420/3.7ms; flipangle, 9 degrees; number of slices, 
176; FOV 256x256mm; 1mm isotropic resolution, and an iPAT factor of 2 using grappa. Cortical grey 
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matter thickness was estimated using the standard presets in FreeSurfer 5.3 
(http://surfer.nmr.mgh.harvard.edu/). 
 
Statistical parametric mapping (SPM) 
All individual parametric maps were non-rigidly transformed to an 11C-MeNER spatial template derived 
from an averaged image of the 12 HC subjects. Statistical Parametric Mapping 12 (SPM12) in Matlab2015b 
was used for between group comparisons of 11C-MeNER binding potentials at a voxel level (two-sample t-
test between PD patients and HC subjects). Parametric maps were smoothed with a 4 mm Gaussian filter, 
and an average cortical grey matter mask was used for explicit masking within the SPM software. Voxel-
level analysis threshold was p < 0.005 (uncorrected) and subsequently a family-wise error (FWE) cluster-
level correction at p < 0.05 was applied. Surface projections of resulting voxels were overlaid on a rendered 
brain of one HC subject. 
 
Statistical analysis 
We analyzed the data with the Statistical Package for the Social Sciences (SPSS) version 24. Group data 
were presented as mean ± standard deviation. Group comparisons were interrogated with the Student’s t, 
Mann-Whitney, and Chi-square statistics as appropriate; a normal distribution of data was assessed with the 
Shapiro-Wilk test. Volume of interest (VOI) analysis of BPND values was tested with a repeated measures 
analysis of variance (ANOVA). Significance was accepted at p < 0.05. 
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Results 
Demographic and clinical characteristics of PD patients and HC subjects are summarized in table 1. Groups 
did not differ with regards to age, sex and MoCA scores. In the voxel-wise comparison, SPM localised 
lower cortical 11C-MeNER binding in PD patients tracking the primary motor cortex and, to a lesser extent, 
the primary sensory cortex (Figure 1A). Similarly, VOI analysis of the precentral and postcentral gyrus 
showed significant reduced 11C-MeNER BPND values in PD patients (ANOVA, p = 0.006; precentral left 
0.166 ± 0.081 vs. 0.044 ± 0.123, p = 0.003, precentral right 0.124 ± 0.087 vs. 0.022 ± 0.122, p = 0.012, 
postcentral left 0.131 ± 0.074 vs. 0.022 ± 0.127, p = 0.008, postcentral right 0.125 ± 0.96 vs. 0.016 ± 0.115, 
p = 0.006). To correct for potential partial volume effects on binding signals, we compared cortical thickness 
of the primary motor cortex between groups, which did not differ between PD patients and HC subjects 
(2.44 ± 0.20 versus 2.43 ± 0.24 mm; p = 0.80, and for primary sensory cortex 1.94 ± 0.13 versus 1.95 ± 0.18 
mm; p = 0.76, respectively). Subgroup analysis of PD patients divided by a cut-off at Hoehn & Yahr stage 
2.5 (resulting in n = 15 PD subjects in each group), revealed more widespread reductions of 11C-MeNER 
binding in PD patients with a higher disease stage when contrasted against healthy controls (Figure 1B). 
However, a direct comparison of mild and more severely affected PD groups revealed no significant NAT 
cortical binding differences. 
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Discussion 
Previous 11C-MeNER studies on PD patients from our group targeted subcortical high binding areas of 
MeNER and revealed a reduced 11C-MeNER signal in the thalamus and hypothalamus as well as brainstem 
nuclei.8,12 Using the recently proposed imaging analysis approach for cortical MeNER uptake from 
Moriguchi and colleagues,9 we here report first in vivo evidence of impaired noradrenergic function in the 
primary motor cortex in PD patients using a specific PET ligand for noradrenergic transporter binding. 
Additionally, we show that patients with more advanced clinical disease have a greater decline of 11C-
MeNER uptake in the primary motor cortex. 
Growing evidence suggest an involvement of multiple neurotransmitters in PD and, in line with the results 
from the present study, point to significant dysfunction of the noradrenergic system associated with more 
severe motor disability.4,13,14 The LC is affected by alpha synuclein aggregates in Braak stage 2 of PD during 
its trajectory which precedes and may even surpass later involvement of the substantia nigra.15,16 Evidence 
from animal studies has implicated noradrenergic dysfunction in the appearance and aggravation of motor 
symptoms. Several studies reported that deficient noradrenergic innervation accompanied dopaminergic cell 
loss in toxin-derived PD models.17-19 In mice with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) 
induced dopaminergic lesions, the PD-like motor phenotype is only manifested when there is also 
noradrenergic co-deficiency.20 Noradrenaline deficits also attenuated beneficial levodopa replacement 
effects on motor symptoms in rats lesioned with 6-hydroxydopamine.14 Additionally, amphetamines could 
restore locomotor activity in a dopamine-independent way in a novel PD mouse model.21 Data on 
manipulation of the noradrenergic system to improve motor function in human PD is scarce. One small 
scale, open-label study trialled duloxetine, a combined serotonin and noradrenaline reuptake inhibitor 
(SNRI), and reported beneficial effects on motor symptoms in PD.22 Of note, paroxetine, which is a selective 
serotonin reuptake inhibitor (SSRI), did not improve motor symptoms.23 Methylphenidate, which is a dual 
dopamine and noradrenaline reuptake inhibitor, showed beneficial effects on motor symptoms in PD; 
however, its effects became insignificant with co-administration of high doses of levodopa.24,25 The 
noradrenergic prodrug droxidopa is approved for orthostatic hypotension in PD and was reported to improve 
UPDRS III scores in one study.26 
PD is pathologically characterized not only by perturbed function of the substantia nigra and basal ganglia 
circuitry, but also of cortical networks, including dysfunction of primary motor cortex connections.27-30 
Neural plasticity of the primary motor cortex is altered in PD,31 and facilitation of its excitability by 
transcranial direct current stimulation has shown to improve motor performance in PD patients.32 
Concordantly, abnormal suppression of electroencephalographic activity during a motor task was observed 
in PD patients.33 Using 18F-DOPA PET, Moore and colleagues reported that the primary motor cortex 
exhibited a monoaminergic deficit in early PD which then spread anteriorly and laterally with disease 
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progression.6 A cortical deficit of the noradrenergic system has also been reported in a post-mortem study.2 
Our in vivo results confirm a noradrenergic influence on motor symptoms and altered functioning of the 
primary motor cortex in PD.   
Several limitations of our study have to be mentioned. Cortical binding potentials of 11C-MeNER tend to be 
low, lowering statistical power.9 However, we recruited a relatively robust number of 42 subjects for PET 
and employed corrected SPM analyses as well as VOI based statistics. As specific binding was very low in 
the cortex of PD patients, we also minimized subgroup analysis to avoid low statistical power. Larger sample 
sizes and future noradrenergic PET ligands with higher signal to noise properties may be able to detect more 
subtle deficits in PD and might facilitate analysis of specific PD subgroups and their association to cortical 
noradrenergic innervation. These studies should also address laterality of PD symptoms and its correlation 
to cortical noradrenergic innervation. We also did not assess potential reductions of other monoamines. 
Future studies using multi-tracer approaches are needed for quantifying and comparing deficits of specific 
monoamines in the motor cortex of PD.6 
In conclusion, this study provides in vivo evidence for altered noradrenergic transmission in the motor cortex 
in PD patients, which is associated with greater disease severity. Thus, our results suggest that noradrenergic 
dysfunction make a contribution to the motor deterioration in PD.  
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Figure legend 
 
Figure 1: Reduction of 11C-MeNER binding in the motor cortex of PD patients 
Voxels with significantly lower 11C-MeNER binding potentials in PD patients compared to HC subjects are 
given in purple. Maps were derived with statistical parametric mapping 12 (SPM 12) using a voxel threshold 
of p < 0.005 (uncorrected) and a cluster threshold of p < 0.05 with family-wise error correction. A: 
Comparison of all 30 PD patients contrasted against 12 HC subjects. B: Subgroup analysis of PD patients 
with Hoehn & Yahr stage <2.5 (left; n = 15) and patients with Hoehn & Yahr stage ≥2.5 (right; n = 15) 
contrasted against 12 HC subjects. In PD patients with Hoehn & Yahr stage <2.5, voxels with threshold at 
p < 0.005 (uncorrected) are presented without cluster correction as no cluster survived the family-wise error 
cluster correction. Abbreviations: HC = healthy control, PD = Parkinson’s disease. 
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Tables 
 
Table 1: Demographics and clinical characteristics  
 HC (n=12) PD (n=30) P-value 
Age 67.3 ± 6.3 66.6 ± 9.1 nsǂ 
Sex (male / female) 9 / 3 22 / 8 ns§ 
Sniffing sticks, correct 11.1 ± 2.8 7.1 ± 2.7 <0.001ǂ 
GDS-15, total 0.2 ± 0.4 1.0 ± 1.4 ns¤  
MoCA, total 28.3 ± 0.9 26.8 ± 2.2 ns¤ 
PD characteristics    
Disease duration [years]  6.4 ± 4.3  
Hoehn & Yahr  2.3 ± 0.5  
MDS-UPDRS III, total  36.1 ± 11.5  
LEDD [mg]  620 ± 404  
RBD (yes / no)  16 / 14  
ǂ = parametric test (Student’s t-test), ¤ = non-parametric test (Mann-Whitney test), § = χ² test. Abbreviations: 
GDS-15 = Geriatric Depression Scale, HC = healthy control subject, LEDD = levodopa daily equivalent 
dose, MDS-UPDRS III = Movement Disorder Society Unified Parkinson’s disease Rating Scale part III, 
MoCA = Montreal Cognitive Assessment, ns = not significant, PD = Parkinson’s disease, RBD = REM 
sleep behavior disorder. 
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Supplementary material 
11C-MeNER PET image acquisition and reconstruction 
The synthesis of 11C-MeNER was performed accordingly to a previously published protocol.1 A six minute 
transmission scan was acquired for attenuation correction prior to each 11C-MeNER emission scan. 
Radiotracer was intravenously injected and 11C-MeNER doses did not differ between groups (HC, 646.3 ± 
119.6, PD, 707.6 ± 106.5 MBq; p = 0.146). Dynamic PET was acquired over 90 minutes in list-mode on a 
Siemens high-resolution research tomograph (HRRT) and then rebinned into 27 time frames (6 x 30 s, 3 x 
60 s, 2 x 120 s, and 16 x 300 s). Image series were reconstructed using 3D OSEM (ordered subsets 
expectation maximization) and resolution recovery modelling (PSF) with 10 iterations and 16 subsets. 
Reconstructed images consisted of 207 axial image slices with an isotropic 1.22 mm voxel size. 
Reconstructed images were processed with PMOD 3.8 and its relevant toolboxes, including time frame 
realignment for motion correction. All PET images were then normalized into Montreal Neurological 
Institute (MNI) space including rigid matching of subject’s PET to the anatomical magnetic resonance 
image (MRI), and MRI segmentation using the PNEURO tool. Volumes of interest (VOIs) of the caudate, 
thalamus and precentral as well postcentral gyrus were extracted from the PMOD built-in atlas. 
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